Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

Mr. Enrico Cañal Bruland, General Manager, Novo Nordisk Pharma (Thailand ... support in empowering people with diabetes to lead fulfilling lives, pursue education, careers, and reach their ...

A larger body doesn’t necessarily mean you have ‘clinical obesity’, according to a proposed new definition of the disease.

Given its low valuation and the seeming overreaction in the markets to the recent trial results, this is a stock that could ...

Diabetes specialist Novo Nordisk is feeling the heat from increasingly price conscious US payers. It needs next generation innovation and growth in emerging markets to keep ahead of competitors ...

There's no doubt that self-injection devices have transformed the lives of people with chronic diseases like diabetes ... according to Novo Nordisk. "Up to 85% of the materials in every pen ...

While the recent launches of GLP-1 drugs from Novo Nordisk and Eli Lilly have been ... managed to largely erase their diabetes and obesity medicines from the FDA’s online shortage roster.

“Without access to diabetes educators who speak the same languages as our patients, diabetes-related education ... Abbott, Novo Nordisk, Eli Lilly and Company, Sanofi, and Insulet.

DelveInsight's Mild Cognitive Impairment Market Insights report includes a comprehensive understanding of current treatment ...

According to DelveInsight's analysis, the mild cognitive impairment market is anticipated to increase during the forecast period (2024-2034), owing to the rise in the launch of emerging therapies ...